Research

The European Medicines Agency (EMA) is looking for new data partners to collaborate with DARWIN EU® - the Data Analysis and Real-World Interrogation Network.

The EAN is pleased to announce the creation of a new Coordinating Panel on Functional Neurological Disorders. All EAN Individual Members with an interest in this field are encouraged to apply!

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for September 2023.

The EAN is looking for a candidate who will provide support to the EAN Guideline Production Group and Guideline Taskforces as a Junior Methodologist.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2023.

Help increase awareness of brain-injury-specific commonalities for a chance to win free registration for EAN 2024.

Please take this survey, even if you currently do not have access to genetic testing, and help ILAE establish the state of genetic testing worldwide.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for June 2023.

One full bursary and three free registrations are yours to be won by participating in our survey on general neurology.

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

Watch a full recording of the European Brain Health Summit 2023, held on 9 May, featuring key international voices on precision neurology and the prevention of neurological diseases.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.